Share

Print

Press Releases

• AIDS vaccine trial results, while disappointing, must guide continuing search; research for vaccine and other new HIV prevention options must continue
  Apr 25, 2013
  The announcement today that immunizations in a large-scale HIV vaccine trial have been stopped early after an independent scientific review board determined that the vaccine being tested is not effective is a reminder of how challenging it is to develop an effective AIDS vaccine, AVAC said.    more...
• New Report on Global HIV Treatment Research and Development Investments in 2010 and 2011
  Mar 6, 2013
  The Treatment Action Group (TAG) and AVAC released their latest report, Funding Scientific Innovation: Global Investments in HIV Treatment Research and Development in 2010 and 2011.    more...
• VOICE Trial Results Underscore Need to Accelerate Development of Additional HIV Prevention Options for Women: PrEP strategies remain valuable prevention tool, says AVAC
  Mar 4, 2013
  Results from a large-scale HIV prevention trial among African women known as VOICE (Vaginal and Oral Interventions to Control the Epidemic) provide an urgent reminder that products must meet the needs of the people using them.    more...
• AVAC Statement on PEPFAR Blueprint
  Nov 29, 2012
  The blueprint also recognizes that ending AIDS will not be easy or quick. While current options can have a tremendous impact, continued science and innovation are essential to ultimately halt new HIV infections and deaths from AIDS.    more...
• AVAC Report Finds That World is Already Falling Behind Pace to End AIDS Epidemic; Five Essential Actions Needed in 2013 to Avoid Historic Missed Opportunity
  Nov 27, 2012
  AVAC released "Achieving the End: One Year and Counting," offering its critical assessment of progress achieved since global leaders began to discuss the opportunity to begin to end AIDS in late 2011.    more...
• AVAC welcomes CDC guidance on PrEP for heterosexual men and women; calls for more demonstration projects to help guide optimal PrEP use
  Aug 9, 2012
  AVAC today welcomed CDC guidelines on the use of the antiretroviral drug TDF/FTC or Truvada as pre-exposure prophylaxis (PrEP) among sexually active heterosexual men and women.    more...
• African Leaders at International AIDS Conference Call for Scaling up Services in East and Southern Africa for Male Circumcision, an Evidence-based HIV Prevention Intervention
  Jul 23, 2012
  Three clinical trials have proven that VMMC can reduce female to male transmission of HIV by approximately 60%. If scaled up to reach 80% of adolescents and adult men within five years, and coverage is thereafter maintained, VMMC has the potential to avert more than 3.4 million new HIV infections...    more...
• amfAR and AVAC Launch Global Action Agenda for Ending AIDS; Report Lays out Policy Priorities and Milestones through 2015 to Hasten a “Tipping Point” in Drive to End AIDS
  Jul 19, 2012
  Two of the world’s leading AIDS advocacy organizations today released a global action agenda aimed at accelerating progress towards the end of the AIDS epidemic. The recommended actions could accelerate achievement of a “tipping point” in the global AIDS epidemic, at which the number of...    more...
• AVAC Welcomes Landmark FDA Approval of (Truvada) TDF/FTC as PrEP for HIV – Urges Immediate Steps to Make Important New HIV Prevention Option Available for the Men and Women Who Need It
  Jul 16, 2012
  AVAC today hailed the decision by the US FDA to approve the antiretroviral drug TDF/FTC or Truvada for use as PrEP among sexually active HIV-negative adult men and women.    more...
• African and US AIDS Advocates Issue a Call to Action Ahead of the International AIDS Conference Urging Global Leaders to Make Voluntary Medical Male Circumcision a Priority
  Jul 12, 2012
  African Advocates Launch Movement to Build Support for Voluntary Medical Male Circumcision in Key Countries and Establish www.TruthAboutVMMC.org    more...
• Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women; AVAC Lays out Priorities to Ensure Access
  Jul 11, 2012
  Publication of data from three trials of pre-exposure prophylaxis (PrEP) for HIV provides strong evidence that HIV-negative men and women who consistently take a daily antiretroviral (ARV) pill can significantly reduce their risk of HIV infection.    more...
• AVAC Urges FDA Approval of PrEP Following Positive Advisory Committee Recommendation; Lays out Priorities to Ensure Access
  May 10, 2012
  AVAC hails the recommendation by an FDA Advisory Committee that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women.    more...
• Leading AIDS Advocates Support FDA Approval of Pre-Exposure Prophylaxis (PrEP), a Promising New HIV Prevention Method, for Men and Women
  May 1, 2012
  A group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of TDF/FTC or Truvada as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult men and women.    more...
• AVAC praises California’s HIV PrEP demonstration studies: More projects needed to translate science into reduced HIV infections, saved lives
  Apr 23, 2012
  AVAC strongly supports the California HIV/AIDS Research Program (CHRP) in launching new studies to evaluate the “real-world” use of oral pre-exposure prophylaxis (PrEP).    more...
• AVAC welcomes Gilead’s submission of PrEP Data to FDA; Full review of all available data will help point the way forward for Truvada for PrEP use
  Dec 15, 2011
  Gilead Sciences announced that it has submitted a dossier of research data to the FDA related to the use of the antiretroviral treatment drug TDF/FTC as a pre-exposure prophylaxis (PrEP) HIV prevention strategy.    more...
• AVAC Report Defines Agenda for Ending the Global AIDS Epidemic
  Nov 30, 2011
  AVAC today issued a science-based agenda for ending the AIDS epidemic within our lifetimes. The new report, titled The End?, is a unique strategic vision encompassing key steps to accelerate impact with existing HIV prevention tools, emerging strategies and longer term research.    more...
• VOICE trial changes are disappointing, says AVAC; Calls for continued research to find new prevention options for women
  Nov 25, 2011
  The announcement today that the 1% tenofovir gel arm of a large-scale HIV prevention trial known as VOICE will stop early is disappointing but is not the end of the road for tenofovir gel or antiretroviral (ARV)-based microbicides.    more...
• AVAC Applauds Secretary of State Hillary Clinton for Ambitious, Science-Based Vision to End the AIDS Epidemic
  Nov 8, 2011
  AVAC welcomes today’s remarks by U.S. Secretary of State Hillary Rodham Clinton as the first step in an ambitious vision for ending the global AIDS epidemic and calls for expanded HIV testing, full implementation of recent biomedical breakthroughs.    more...
• An Open Letter to the US Food and Drug Administration and Gilead Sciences
  Oct 18, 2011
  We urge the FDA and Gilead Sciences to reconsider plans to combine the approval for a prevention indication for both men who have sex with men, including transgender populations (MSM) and heterosexuals into a single filing. The combination could unnecessarily delay approval for MSM, the group at...    more...
• HIV/AIDS Organizations Tell FDA and Gilead Sciences: Don’t Delay HIV Prevention for Gay and Bisexual Men and Transgender Women
  Oct 18, 2011
  Thirteen prominent U.S. HIV/AIDS organizations have issued an open letter to the U.S. Food and Drug Administration and Gilead Sciences calling for prompt regulatory review of pre-exposure prophylaxis (PrEP) for HIV prevention in gay and bisexual men and transgender women (men who have sex with...    more...
• AVAC says VOICE trial changes are disappointing, but do not close the door on PrEP for women; Continued PrEP research more important than ever
  Sep 28, 2011
  The announcement today that one arm of a large-scale HIV prevention trial known as VOICE will stop early is disappointing, but must be seen in context, according to the global advocacy organization AVAC.    more...
• Open letter from HIV-positive prevention advocates rejects misinformation about pre-exposure prophylaxis (PrEP)
  Sep 15, 2011
  A copy of the sign-on letter supporting an informed debate on PrEP for gay and bisexual men is below. Openly HIV-positive gay and bisexual men who wish to add their name to the letter can do so at: http://tinyurl.com/pozPrEPletter.    more...
• Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs
  Jul 19, 2011
  The report argues that capitalizing on recent promising scientific breakthroughs will require substantial additional and sustained investment from a broader set of donors.    more...
• AVAC says results of new PrEP trials provide clear evidence that antiretroviral drugs for prevention can help end the AIDS epidemic; calls for quick action on results
  Jul 13, 2011
  Results from two African studies of pre-exposure prophylaxis, or PrEP, released today provide clear evidence that the antiretroviral drugs used to treat HIV can also be used to prevent HIV among heterosexual men and women at risk of HIV infection.    more...
• Activists and Researchers: Evidence Shows We Can End the AIDS Epidemic; International coalition calls for clear actions from world leaders
  Jun 7, 2011
  An international coalition of scientists and activists today launched a common platform for ending the AIDS epidemic. The broad-based international coalition issued a statement calling for world leaders to support a rational, evidence-based approach to responding to AIDS.    more...
• HPTN 052 trial confirms ARV treatment is a powerful prevention tool: “Early initiation of treatment will be fundamental to turning the tide of the epidemic,” AVAC says
  May 12, 2011
  The sponsors of a randomized clinical trial known as HPTN 052, which is evaluating combination antiretroviral therapy for HIV prevention, announced that randomization would halt due to overwhelming evidence of benefit.    more...
• Discontinuation of the FEM-PrEP Trial Disappointing, AVAC Says; Calls for continued research to find new ways to end the HIV epidemic
  Apr 18, 2011
  The Independent Data Monitoring Committee for the FEM-PrEP study determined that the trial be discontinued. This is disappointing but there are reasons to be hopeful.    more...
• New report provides women's perspectives on medical male circumcision for HIV prevention: Findings from community-led research in five African countries
  Dec 13, 2010
  A new report from the Women’s HIV Prevention Tracking Project (WHiPT), a collaborative initiative of AVAC and the ATHENA Network, features an unprecedented collection of voices from Kenya, Namibia, South Africa, Swaziland and Uganda reflecting on what male circumcision for HIV prevention means...    more...
• Evidence that daily antiretroviral pill reduces HIV risk in gay men is a major breakthrough says AVAC: Public health agencies and communities must move quickly to translate trial results into impact
  Nov 23, 2010
  “This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV...    more...
• AVAC Calls for AIDS Vaccine Field to Implement New Scientific Strategic Plan Released by Global HIV Vaccine Enterprise
  Sep 7, 2010
  AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.    more...
• AVAC Calls for Speedy Funding of Critical Microbicide Follow-Up Studies
  Sep 3, 2010
  New York, NY, 3 September 2010 – AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as...    more...
• Preliminary Safety and Adherence Data from Oral PrEP Trial Released; Trial Not Designed to Evaluate Effectiveness
  Jul 23, 2010
  New York, NY – Preliminary data were presented today at the International AIDS Conference by the US Centers for Disease Control and Prevention (CDC) from a safety and acceptability trial of daily use of oral tenofovir in HIV-negative gay men and other men who have sex with men (MSM) in the...    more...
• New Edition of Guidelines for Involving Communities in HIV Prevention 
Research Released at International AIDS Conference
  Jul 23, 2010
  AVAC Contact: Kay Marshall, +1-347-249-6375, kay@avac.org UNAIDS Contact: Saya Oka, +41 22 791 1697, okas@unaids.org GPP Plays Critical Role in Moving HIV Prevention Research Agenda Forward VIENNA – The draft second edition of The Good Participatory Practice (GPP) Guidelines for...    more...
• Report Warns Flat Funding for HIV Prevention Research May Limit Ability of Researchers to Move Promising Approaches Forward
  Jul 21, 2010
  VIENNA (21 July, 2010) – Following significant advances in vaccine and microbicide research, importantly including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention...    more...
• Study of Microbicide Gel Shows Reduced Risk of HIV & Herpes Infections in Women
  Jul 20, 2010
  “This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection,” said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide...    more...
• Turning the Page to a New Era in HIV Prevention Research: AVAC Report warns promising developments in biomedical HIV prevention could be undermined by current conditions of the global AIDS response
  Jul 14, 2010
  A new report from AVAC surveys the state of biomedical HIV prevention research, including the first evidence of vaccine-induced protection in humans and the emergence of ARV-based prevention—and provides strategic recommendations for moving forward in a time of constrained resources and...    more...
• AVAC Says MDP 301 Microbicide Trial Results Disappointing, But Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
  Dec 14, 2009
  New York, NY, December 14, 2009 — The Microbicides Development Programme announced earlier today that its MDP 301 effectiveness trial, which was conducted among almost 9,400 women in four African countries, found no evidence that the PRO 2000 microbicide reduces the risk of HIV infection.    more...
• AVAC Praises Thai AIDS Vaccine Trial Collaborators and Volunteers for Historic Study
  Sep 24, 2009
     Category: Publications
  New York, NY, , "Today marks an historic milestone in the search for an AIDS vaccine; we now have evidence that it is possible to reduce the risk HIV infection with a vaccine," said AVAC executive director Mitchell Warren, reacting to the results of the first AIDS vaccine trial to ever show...    more...   
• Shifting Scientific, Health Priorities and Global Economic Downturn Impact Investment in HIV Prevention R&D
  Jul 20, 2009
  Cape Town -- A new report on investment in HIV prevention research in 2008 finds that HIV vaccine research funding levels decreased for the first time since investment trends have been tracked. This may have been influenced by shifts in scientific priorities, the declining economy and competing...    more...
• Piecing Together the HIV Prevention Puzzle: AVAC Report Assesses Progress in AIDS Vaccine, Microbicide and PrEP Research and Calls for Urgent Coordination and Leadership in Advance of Upcoming Results
  May 18, 2009
  New York, NY -- "It's an exciting time in HIV prevention research. We will see results from a number of critically important HIV prevention research trials this year, as well as see the start of new trials around the world that will yield important answers in the years to come," said Mitchell...    more...
• Clearinghouse on Male Circumcision for HIV Prevention Web Site Launched
  Feb 23, 2009
  The Clearinghouse on Male Circumcision for HIV Prevention , www.malecircumcision.org , was launched today. The Web site is designed to generate and share authoritative information about the role of male circumcision in HIV prevention.    more...
• New Report Finds Investment in AIDS Vaccine and Microbicide R&D Continues to Increase Incrementally in 2007: Calls for Sustained Funding to Maintain HIV Prevention Research Efforts
  Aug 5, 2008
  Mexico City, August 5, 2008 -- A new report released today shows that funding for biomedical HIV prevention research and development (R&D), including AIDS vaccines and microbicides, increased dramatically between 2000 and 2006 with only a modest increase in 2007. The report warns that the...    more...
• New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option:
  Aug 3, 2008
  Mexico City, Mexico, August 3, 2008 -- The AIDS Vaccine Advocacy Coalition (AVAC) today released a new report, Anticipating the Results of PrEP Trials, calling for increased action from governments, global health institutions, donors, researchers, and advocates to prepare for initial results --...    more...
• Immunizing Against Misinformation and Shortsightedness: AVAC Report Injects a Dose of Reality into the Debate on the State of AIDS Vaccine Research
  May 15, 2008
  New York, NY , The AIDS Vaccine Advocacy Coalition (AVAC) today released a new report that provides a comprehensive review of recent developments in AIDS vaccine research. AVAC Report 2008: The Search Must Continue explores the issues that have been raised in the wake of the failure of Merck's...    more...
• Safety of Trial Volunteers Must Remain Paramount Concern
  Nov 7, 2007
  Contact: Mitchell Warren, +1-914-661-1536, mitchell@avac.org Seattle, Washington, November 7, 2007, The AIDS Vaccine Advocacy Coalition (AVAC) released the following statement today from Executive Director Mitchell Warren in response to the release of new data from the STEP AIDS vaccine study...    more...
• AVAC Statement on Phambili and STEP trials: Trial Participant Safety is the Top Priority
  Oct 26, 2007
  New York and Johannesburg -- The AIDS Vaccine Advocacy Coalition (AVAC) issued the following statement with regard to recent announcements about the Phambili AIDS vaccine trial in South Africa.    more...
• AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result - Applauds Merck's Leadership and Calls for Reinvigorated Effort to Design and Test AIDS Vaccines
  Sep 21, 2007
  The AIDS Vaccine Advocacy Coalition (AVAC) released the following statement from Executive Director Mitchell Warren about the announcement that vaccinations have been discontinued in the STEP Study, a test-of-concept trial of the MRK-Ad5 AIDS vaccine candidate developed by the Merck Research...    more...
• AIDS Vaccine Advocacy Coalition Receives $14 Million Grant from Gates Foundation to Develop International HIV Prevention Research Advocacy Network
  Aug 21, 2007
  New AVAC Report on the State of the AIDS Vaccine Field Calls for Accelerated Action in AIDS Vaccine and HIV Prevention Research Seattle -- The AIDS Vaccine Advocacy Coalition (AVAC) announced today at the AIDS Vaccine 2007 Conference that it has received a five-year, $14 million grant from the...    more...
• AIDS Vaccine Advocacy Coalition calls for renewed commitment to vaccine research on anniversary of President Clinton's 10-year challenge
  May 16, 2007
  Call for new urgency, targets and leadership to accelerate research on HIV Vaccine Awareness Day New York, NY -- On May 18, 1997, US President Bill Clinton called for a concerted effort to develop an AIDS vaccine within a decade. This year we mark the 10th anniversary of that call for action...    more...
• AIDS Vaccine Advocacy Coalition Calls for Strategic Leadership and Urgency in the Implementation of Male Circumcision for HIV Prevention
  Mar 28, 2007
  New York, NY -- Mitchell Warren, Executive Director of the AIDS Vaccine Advocacy Coalition (AVAC) today issued the following statement regarding the new recommendations from the World Health Organization (WHO) and UNAIDS on male circumcision as an HIV prevention strategy.   "AVAC...    more...
• AVAC Applauds Commencement of First HIV Vaccine Efficacy Trial in Africa
  Feb 8, 2007
  New York, New York -- The AIDS Vaccine Advocacy Coalition (AVAC) heralds today's launchof the first African efficacy trial of an experimental HIV vaccine as a critical, strategic and historically-significant step in the search for an AIDS vaccine.    more...
• Leading advocates express support for microbicide research, despite disappointing clinical trial results.
  Jan 31, 2007
  HIV prevention advocates from three major civil society organizations today emphasized the importance of continued research into new HIV prevention options, despite the recent discontinuation of the Phase III effectiveness trials of the microbicide candidate, cellulose sulfate (CS).    more...
• AVAC Calls for Strategic Leadership in the Implementation of Male Circumcision for HIV Prevention
  Dec 13, 2006
  link doesnt work    more...
• HIV Vaccines and Microbicides Resource Tracking Working Group Releases Preliminary Data and Launches New Website
  Jun 1, 2006
  The HIV Vaccines and Microbicides Resource Tracking Working Group was established in 2004 to generate and disseminate high-quality, detailed and comparable data on annual investments in preventive HIV vaccine and microbicide research and development (R&D), and policy and advocacy activities....    more...
• Launch of AIDS Vaccine Clearinghouse
  May 17, 2006
  The AIDS Vaccine Advocacy Coalition (AVAC) is delighted to announce the launch of its new AIDS Vaccine Clearinghouse, a comprehensive and interactive source of AIDS vaccine information on the Internet. The website, www.aidsvaccineclearinghouse.org, provides a gateway to information and a link to...    more...
• AIDS Vaccine Advocacy Coalition Issues Report on Tenofovir Prevention Trials: Calls for coordinated response to ensure trials continue
  Mar 24, 2005
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today released a report on issues surrounding clinical testing of the antiretroviral drug tenofovir as pre-exposure prophylaxis (PREP) - a possible once-a-day pill for prevention of HIV.    more...
• A public statement from the Global Campaign for Microbicides and the AIDS Vaccines Advocacy Coalition on the impact of stopping Tenofovir trials in Cambodia and Cameroon
  Feb 18, 2005
  Recently clinical trials have been launched in Africa, Asia and the United States to explore the potential use of oral Tenofovir as a "once a day" pill to prevent HIV in uninfected individuals - an intervention known as pre-exposure prophylaxis (PREP). Yet concerns from a few activists opposed to...    more...
• AIDS Advocates Partner to Involve African Americans in search for an AIDS vaccine
  Feb 7, 2005
  LOS ANGELES and NEW YORK, February 7, 2005 -- In recognition of National Black HIV/AIDS Awareness Day, the AIDS Vaccine Advocacy Coalition (AVAC) and the Black AIDS Institute (the Institute) are pleased to announce the release of Myths About HIV Vaccines and Vaccine Research, a fact sheet that...    more...
• AIDS Vaccine Advocates Hail South African Focus on Youth
  Aug 12, 2004
  NEW YORK -- The AIDS Vaccine Advocacy Coalition (AVAC) praised a new partnership between the Nelson Mandela Foundation and the South African AIDS Vaccine Initiative (SAAVI), which was announced today in Johannesburg.    more...
• Government Incentives Should Extend to AIDS Vaccine Development
  Jul 22, 2004
  NEW YORK -- The AIDS Vaccine Advocacy Coalition (AVAC) today hailed new federal legislation that provides financial incentives for private industry to develop vaccines and other antidotes to protect people in the event of biological or chemical weapon attacks.    more...
• Advocacy Group Voices Disappointment: Calls for Reinvigorated Effort to Design and Test AIDS Vaccines
  Nov 12, 2003
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today expressed disappointment that the second Phase III trial of an AIDS vaccine did not show efficacy of the candidate vaccine, AIDSVAX. The trial tested AIDSVAX among 2,546 injection drug users in Thailand. "We are disappointed that...    more...
• Advocacy Group Issues Guide to Forthcoming AIDS Vaccine Trial Results
  Oct 23, 2003
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today released a guide for the public on the forthcoming results of the world's first AIDS vaccine efficacy trial. Results of the clinical trial of AIDSVAX, made by the biopharmaceutical company VaxGen, are expected to be released early in 2003.    more...
• Medicines Control Council Begins Phase I Clinical Trial of South Africa's First AIDS Vaccine
  Jun 19, 2003
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) yesterday applauded South Africa's Medicines Control Council for giving the go-ahead to a long-awaited Phase I clinical trial of the countrys first AIDS vaccine.    more...
• New Industry Survey Finds Need for Increased Government Role in Search for AIDS Vaccine
  May 15, 2003
  Advocacy Group Calls on Congress to Apply Bioterror Incentives in Battle Against Global Infectious Disease NEW YORK - Private industry is stepping up its quest for an AIDS vaccine, but it needs increased government support to maintain the momentum, according to findings of a new survey released...    more...
• Advocacy Group Praises Merck-Aventis Pasteur Vaccine Collaboration
  Mar 27, 2003
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today said it is encouraged by the announcement that Merck & Co. would team up with Aventis Pasteur to work on a potential AIDS vaccine.    more...
• Vaccine Fails to Show Efficacy: Data from subgroup analysis is intriguing But drawing conclusions would raise false hopes
  Feb 24, 2003
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today expressed disappointment that the first efficacy trial of an AIDS vaccine failed to show protection in the study population. The trial was of the vaccine candidate AIDSVAX that is made by VaxGen.    more...
• AIDS Vaccine Advocacy Coalition (AVAC) Announces Appointment of Director of Science Communication and Advocacy
  Jan 30, 2003
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today announced the appointment of Huntly Collins as its first Director of Science Communication and Advocacy. Ms. Collins was a respected staff writer at The Philadelphia Inquirer from 1983 to 2001, where she covered public health and AIDS...    more...
• FORD FOUNDATION MAKES TWO YEAR AWARD TO AIDS VACCINE ADVOCACY COALITION FOR COMMUNITY EDUCATION AND MOBILIZATION
  Jun 25, 2002
  AVAC Announces Appointment of New Director of Education and Outreach NEW YORK - The Ford Foundation today announced a $250,000 grant over two years to the AIDS Vaccine Advocacy Coalition (AVAC). Founded in 1995, AVAC is a community and consumer-based advocacy organization working to accelerate...    more...
• AIDS Vaccine Challenge at Half-Way Mark -- Advocacy Coalition Sounds Alarm --
  May 17, 2002
  NEW YORK - Today, the AIDS Vaccine Advocacy Coalition (AVAC) issued its fifth independent assessment of AIDS vaccine development from a community perspective. Entitled "Five Years & Counting; Science, Urgency and Courage," the report finds that the campaign to identify an effective AIDS vaccine...    more...
• AIDS VACCINE ADVOCATES CALL FOR EXPANDED EFFORTS IN THE WAKE OF NIH ANNOUNCEMENT ON HIV VACCINE EFFORT
  Feb 25, 2002
  NEW YORK - The AIDS Vaccine Advocacy Coalition (AVAC) today responded to an announcement by the National Institutes of Health (NIH) that it would not be able to run a clinical trial of immune responses with the canarypox HIV vaccine candidate. "We are very disappointed that immunology results do...    more...
• Bill & Melinda Gates Foundation Awards Three-Year Grant to AIDS Vaccine Advocacy Coalition (AVAC), AVAC Announces Appointment of New Executive Director
  Jan 23, 2002
  Washington, D.C. - The Bill & Melinda Gates Foundation today announced a grant of $600,000 over three years to the AIDS Vaccine Advocacy Coalition (AVAC). Founded in 1995, AVAC is a consumer-based advocacy organization working to speed development and delivery of AIDS vaccines to populations...    more...
• View Archives